EU/3/09/696: Orphan designation for the treatment of ovarian cancer

Human MHC non-restricted cytotoxic T-cell line

Table of contents


On 30 November 2009, orphan designation (EU/3/09/696) was granted by the European Commission to Abiogen Pharma S.p.A., Italy, for human MHC non-restricted cytotoxic T-cell line for the treatment of ovarian cancer.

The sponsorship was transferred to Galileo Research S.r.l., Italy, in March 2013.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

Key facts

Active substance
Human MHC non-restricted cytotoxic T-cell line
Intended use
Treatment of ovarian cancer
Orphan designation status
EU designation number
Date of designation
Galileo Research S.r.l.
via del Paradiso 6
56019 Vecchiano frazione Migliarino (Pisa)
Tel. +39 050 3154401
Fax +39 050 803338

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating